Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.
Humans
Fusidic Acid
/ pharmacology
Impetigo
/ epidemiology
Staphylococcus aureus
Belgium
/ epidemiology
Anti-Bacterial Agents
/ pharmacology
Multilocus Sequence Typing
Drug Resistance, Bacterial
/ genetics
Staphylococcal Infections
/ epidemiology
Oxacillin
Clone Cells
Methicillin-Resistant Staphylococcus aureus
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
received:
14
03
2023
accepted:
16
06
2023
medline:
3
8
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them. For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton-Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types. Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak. These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.
Identifiants
pubmed: 37358399
pii: 7207651
doi: 10.1093/jac/dkad204
pmc: PMC10393872
doi:
Substances chimiques
Fusidic Acid
59XE10C19C
Anti-Bacterial Agents
0
Oxacillin
UH95VD7V76
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2061-2065Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Scand J Infect Dis. 2014 Dec;46(12):832-7
pubmed: 25229166
Trop Med Infect Dis. 2021 Nov 09;6(4):
pubmed: 34842831
Antimicrob Agents Chemother. 1996 Dec;40(12):2820-3
pubmed: 9124848
J Clin Microbiol. 2007 Jan;45(1):127-33
pubmed: 17093021
Methods Mol Biol. 2009;551:189-202
pubmed: 19521876
J Clin Microbiol. 2002 Apr;40(4):1514-7
pubmed: 11923385
Clin Exp Dermatol. 2005 Sep;30(5):512-4
pubmed: 16045681
J Clin Microbiol. 2007 May;45(5):1505-10
pubmed: 17344365
Rev Mal Respir. 2012 Nov;29(9):1174-8
pubmed: 23200597
J Antimicrob Chemother. 2012 May;67(5):1176-80
pubmed: 22290345
Euro Surveill. 2022 Dec;27(49):
pubmed: 36695440
Drugs. 2008;68(6):855-73
pubmed: 18416589
J Clin Microbiol. 2003 Dec;41(12):5442-8
pubmed: 14662923
Infect Immun. 2002 Feb;70(2):631-41
pubmed: 11796592
Emerg Infect Dis. 2003 Aug;9(8):978-84
pubmed: 12967497
Cochrane Database Syst Rev. 2012 Jan 18;1:CD003261
pubmed: 22258953
J Antimicrob Chemother. 2009 Feb;63(2):420-1; author reply 421
pubmed: 18978362